J Ayub Med Coll Abbottabad 2009;21(1)

http://www.ayubmed.edu.pk/JAMC/PAST/21-94 1/Khairunnisa.pdf
GESTATIONAL TROPHOBLASTIC DISEASE: EXPERIENCE AT
NAWABSHAH HOSPITAL
Khairunnisa Nizam, Gulfareen Haider*, Nizamuddin Memon**, Ambreen Haider†
Department of Obstetrics and Gynaecology, Nawabshah Medical College Hospital, Nawabshah, *Department
of Obstetrics and
Gynaecology, Isra University Hospital, **Department of Radiology, †Department of Cardiology, Liaquat
University of Medical Health
Sciences Hospital, Hyderabad, Pakistan
Background: Gestational Trophoblastic Disease (GTD) is a heterogeneous group of diseases that
includes partial and complete hydatidiform mole, invasive mole, choriocarcinoma and placental site
trophoblastic tumour. The incidence of GTD varies in different parts of the world. The malignant
potential of this disease is higher in South East Asia in comparison to western countries. Objectives of
study were to determine the frequency, clinical presentation and management outcomes of GTD. This
retrospective, descriptive case series was conducted in the Department of Obstetric and Gynaecology
Nawabshah Medical College Hospital, from 1st Jan 2007 to 30th Dec 2007.
Methods: The case records
of all the gestational trophoblastic cases during study period were analysed regarding their history,
clinical examination, investigations, treatment and follow-up. The main outcomes were measured in
terms of duration, antecedent pregnancy, investigations, treatment and the follow-up.
Results: There
were a total of 1056 Obstetric admissions during the study period, which included 30 cases of
trophoblastic disease with a frequency of GTD was 28 per 1000 live births. Of these 30 cases, 21 (70%)
patients had hydatidiform mole, 7 (23.3%) patients had invasive disease and 2 (6.6%) patients had
choriocarcinoma. Twenty three patients (76.6%) received chemotherapy while 25 (83.3%) patients had
suction evacuation and 4 (13.3%) patients underwent hysterectomy. Among all patients, 29(96.7%)
fully recovered and 1 (3.3%) died because of extensive disease; metastasis extending up to brain.
Conclusion: Frequency of GTD was higher compared to national and international studies. The disease
was common in extremes of ages, low para and grand multiparous women. Hydatidiform mole was the
commonest type of trophoblastic disease in these patients. Most common presenting complaint was
bleeding per vagina followed by pain in lower abdomen.
Keywords: Gestational trophoblastic disease, Hydatidiform mole, Management

 Developmental anomaly of the placenta that converts the chorionic villi into a mass of clear fluid-filled
vesicles.
 Two types of moles:

a. Complete moles – neither an embryo nor an amniotic sac. It

is characterized by swelling and cystic formation of all
trophoblastic cells. No fetal blood is present. If an embryo
did develop, it was most likely only 1 to 2 mm in size and
died early on. A complete mole is highly associated with
the development of choriocarcinoma.

b. Partial mole – embryo (usually with multiple anomalies) and

amniotic sac. It is characterized by edema of a layer of the
trophoblastic villi with some of the villi forming normally.
Fetal blood may be present in the villi, and an embryo up
to the size of 9 weeks gestation may be present. Typically,
apartial mole has 69 chromosomes in which there are
three chromosomes for every one pair.

 Major cause of second trimester bleeding.

 Also called molar pregnancy or hydatidiform mole.

Pathophysiology

 Trophoblastic villi cells located in the outer ring of the blastocyst (the structure that develops via cell division
around 3 to 4 days after fertilization) rapidly increase in size, begin to deteriorate, and fill with fluid.
 The cells become edematous, appearing a grapelike clusters of vesicles.
 As a result, the embryo falls to develop past the early stages.

Causes

 Exact cause is unknown

 May be associated with poor maternal nutritional (specifically, an insufficient intake of protein and folic acid),
a defective ovum, chromosomal abnormalities, or hormonal imbalances.
 Preceding molar pregnancy in about 50% of patients with choriocarcinoma.
  Preceding spontaneous or induced abortion, ectopic pregnancy, or normal pregnancy in the remaining 50%
of patients.

Assessment findings

 Disproportionate enlargement of the uterus; possible grapelike clusters noted in the vagina on pelvic
examination.
 Excessive nausea and vomiting, abdominal cramping.
 Intermittent or continuous bright red or brownish vaginal bleeding
 Passage of tissue resembling grapelike clusters.
 Symptoms of gestational hypertension before 20 weeks’ gestation.
 Absence of fetal heart tones.

Test Results:

 Radioimmunoassay of human chorionic gonadotropin (hCG) levels reveals extremely elevated levels of
early pregnancy.
 Histologic examination may reveal the presence of vesicles.
 Ultrasonography performed after 3 months’ gestation reveals grapelike clusters rather than a fetus, an
absence of fetal skeleton, and evidence of a snowstorm-like pattern.
 Hemoglobin level, hematocrit, red blood cells (RBC) count, prothrombin time, partial thromboplastin time,
fibrinogen levels, and hepatic and renal function findings are all abnormal.
 White blood cells count and erythrocyte sedimentation rate are increased.

Treatment:

 Suction and curettage; if indicated.

 Weekly monitoring of beta-hCG levels until normal 3 consecutive weeks.
 Periodic follow-up for 1 to 2 years.
 Pelvic examinations and chest X-rays at regular intervals.
 Emotional support.
 Avoidance of pregnancy until hCG levels are normal (may take up to 1 year).

Nursing Interventions:

 Obtain baseline vital signs.

 Preoperatively observe the patient for signs of complications, such as hemorrhage, uterine infection, and
vaginal passage of vesicles.
 Save any expelled tissue for laboratory analysis.
 Prepare the patient physically and emotionally for surgery, if indicated.
 Postoperatively, monitor vital signs and fluid intake and output, and assess for signs of hemorrhage.
 Encourage the patient and her family to express their feelings.
 Offer emotional support, and help them through the grieving process.
 Help the patient and her family develops effective coping strategies, referring them to a mental health
professional, if needed.

Introduction

Background

Gestational trophoblastic disease (GTD) can be benign or malignant. Histologically, it is classified into hydatidiform
mole, invasive mole (chorioadenoma destruens), choriocarcinoma, and placental site trophoblastic tumor (PSTT).
Those that invade locally or metastasize are collectively known as gestational trophoblastic neoplasia (GTN).
Hydatidiform mole is the most common form of GTN. While invasive mole and choriocarcinoma are malignant, a
hydatidiform mole can behave in a malignant or benign fashion.
Histologic section of a complete hydatidiform mole stained with hematoxylin and eosin. Villi of different sizes
are present. The large villous in the center exhibits marked edema with a fluid-filled central cavity known as
cisterna. Marked proliferation of the trophoblasts is observed. The syncytiotrophoblasts stain purple, while
the cytotrophoblasts have a clear cytoplasm and bizarre nuclei. No fetal blood vessels are in the
mesenchyme of the villi.

[ CLOSE WINDOW ]

Histologic section of a complete hydatidiform mole stained with hematoxylin and eosin. Villi of different sizes
are present. The large villous in the center exhibits marked edema with a fluid-filled central cavity known as
cisterna. Marked proliferation of the trophoblasts is observed. The syncytiotrophoblasts stain purple, while
the cytotrophoblasts have a clear cytoplasm and bizarre nuclei. No fetal blood vessels are in the
mesenchyme of the villi.

No methods exist to accurately predict the clinical behavior of a hydatidiform mole by histopathology. The clinical
course is defined by the patient's serum human chorionic gonadotropin (hCG) curve after evacuation of the mole. In
80% of patients with a benign hydatidiform mole, serum hCG levels steadily drop to normal within 8-12 weeks after
evacuation of the molar pregnancy. In the other 20% of patients with a malignant hydatidiform mole, serum hCG
levels either rise or plateau.1,2

Pathophysiology

A hydatidiform mole is considered malignant when the serum hCG levels plateau or rise during the follow-up period
and an intervening pregnancy is excluded. This occurs in 15-20% of hydatidiform moles.1,2,3

A hydatidiform mole with a fetus or fetal tissue and a triploid karyotype is known as a partial or incomplete mole.
Partial moles also have malignant potential, but only 2-3% become malignant.4,5,6 Cases of partial hydatidiform moles
with lung metastasis have been reported and at least one case of choriocarcinoma on a biopsy from a vaginal
metastasis has been reported in a patient being observed for a partial hydatidiform mole.7,8

An invasive mole has the same histopathologic characteristics of a hydatidiform mole, but invasion of the
myometrium with necrosis and hemorrhage occurs or pulmonary metastases are present.

Histologically, choriocarcinomas have no villi, but they have sheets of trophoblasts and hemorrhage.
Choriocarcinomas are aneuploid and can be heterozygous depending on the type of pregnancy from which the
choriocarcinoma arose. If a hydatidiform mole preceded the choriocarcinoma, the chromosomes are of paternal
origin. Maternal and paternal chromosomes are present if a term pregnancy precedes the choriocarcinoma. Of
choriocarcinomas, 50% are preceded by a hydatidiform mole, 25% by an abortion, 3% by ectopic pregnancy, and the
other 22% by a full-term pregnancy.1 Choriocarcinoma has also been associated with ectopic pregnancy with a
theoretic incidence of 1 in 5333 ectopic pregnancies.9

Placental site trophoblastic tumor is a rare form of gestational trophoblastic neoplasia, with slightly more than 200
cases reported in the literature.10,11 In patients with PSTT, intermediate trophoblasts are found infiltrating the
myometrium without causing tissue destruction. The intermediate trophoblasts contain human placental lactogen
(hPL).12 These patients have persistent low levels of serum hCG (100-1000 mIU/mL). However, serum hCG levels as
high as 108,000 mIU/mL have been reported in patients with PSTT.13 The treatment of PSTT is hysterectomy with
ovarian conservation.14 If the tumor recurs or metastases are present at initial diagnosis, chemotherapy is
administered with variable results.15,16 Radiation therapy may provide local control.
The most frequent sites of metastases of malignant gestational trophoblastic neoplasia are the lungs, lower genital
tract, brain, liver, kidney, and gastrointestinal tract.

In this microphotograph of a choriocarcinoma metastatic to the brain, the neuropil is seen on the right and
the biphasic (2 cell populations) choriocarcinoma is seen to the left with hemorrhage at the left border of the
photograph (H&E stain).

Frequency

United States

Gestational trophoblastic neoplasia is diagnosed in 15-20% of patients with a complete hydatidiform mole and 2% of
partial hydatidiform moles. Lung metastases are found in 4-5% of patients with complete hydatidiform moles and
rarely in cases of partial hydatidiform moles.

Choriocarcinoma occurs in 1 out of 40 hydatidiform moles and in 1 out of 20,000-40,000 pregnancies.1,17

However,only 1 out of 160,000 term pregnancies is followed by a choriocarcinoma.18

International

The international rate of choriocarcinoma has been reported to be as high as 1 in 500-600 pregnancies in India to 1
in 50,000 pregnancies in Mexico, Paraguay, and Sweden.17,19,20 These differences are probably due to differences in
methodology (eg, identification of cases, accuracy of denominator).17,19

Mortality/Morbidity

Patients who have a malignant hydatidiform mole, an invasive mole, or a choriocarcinoma should undergo a
systematic search for metastases. Patients who have metastases are classified as high-risk or low-risk according to
the National Institutes of Health classification.2 The criteria for high-risk metastatic gestational trophoblastic neoplasia
include hepatic or brain metastasis, serum hCG levels greater than 40,000 mIU/mL prior to the initiation of
chemotherapy, duration of disease longer than 4 months, prior unsuccessful chemotherapy, and malignant
gestational trophoblastic neoplasia following a term pregnancy.

 Patients with malignant nonmetastatic or metastatic low-risk gestational trophoblastic neoplasia have an
almost 100% probability of cure with chemotherapy. The probability of cure after chemotherapy for patients
with metastatic high-risk gestational trophoblastic neoplasia is approximately 75%.21
 The probability of a late recurrence after the patient has been in remission (normal serum beta-hCG titers)
for 1 year is less than 1%.2,22

See Prognosis section for more information on recurrence rate.

Race

 Little information is available on international ethnic or racial differences of the incidence of choriocarcinoma.
 In the United States, African Americans have the highest incidence of choriocarcinoma and the lowest
survival rates.23

Sex

Gestational trophoblastic neoplasia affects women during their reproductive years. However, placental site
trophoblastic tumors have been diagnosed when patients were postmenopausal.

Age

The incidence of choriocarcinoma increases with age and is 5-15 times higher in women 40 years and older than in
younger women.19
Clinical

History

Most cases of gestational trophoblastic neoplasia are diagnosed when the serum hCG levels plateau or rise in
patients being observed after the diagnosis of hydatidiform mole. If metastases are present, signs and symptoms
associated with the metastatic disease, such as hemoptysis, abdominal pain, hematuria, and neurologic symptoms,
may be present.

Physical

 Metastasis to the lower genital tract present as purple to blue-black papules or nodules. These are
extremely vascular and might bleed profusely if biopsied.24
 Abdominal tenderness may be present if  liver or gastrointestinal metastases have occurred.
 Abdominal guarding and rebound tenderness may be present if a hemoperitoneum has occurred due to
bleeding from an abdominal metastasis. Bleeding from a metastasis could also result in signs and symptoms
of hemorrhagic shock.25,26
 Neurologic deficits, from lethargy to coma, can be encountered if brain metastasis has occurred.
 Jaundice may be present if liver metastasis causes biliary obstruction.

Causes

Why some hydatidiform moles become malignant and others do not is unknown. However, mounting evidence shows
different molecular profiles between nonmalignant and malignant gestational trophoblastic disease

Treatment

Medical Care

Patients with gestational trophoblastic disease (GTD) do not require medical therapy. Because 20% of patients with
hydatidiform mole develop malignant disease, such as persistent hydatidiform mole with or without metastasis, some
have suggested the use of a prophylactic dose of methotrexate in noncompliant patients.39,40 However, observing
patients with weekly serum hCG levels is preferable, and only patients with rising or plateauing titers, as occurs in
patients with gestational trophoblastic neoplasia (GTN), should be treated with chemotherapy.1

Patients with nonmetastatic GTN or metastatic low-risk GTN are treated with single-agent chemotherapy.41,42,43,44,45,46
Many in the United States prefer methotrexate. However, actinomycin D can be used in patients with poor liver
function. During treatment, the serum hCG levels are monitored every week. One additional course of chemotherapy
is administered after a normal serum hCG level. After 3-4 normal serum hCG levels, the levels are observed once per
month for 1 year. A switch from methotrexate to actinomycin D is made if the patient receiving methotrexate for
nonmetastatic or metastatic low-risk GTN develops rising or plateauing serum hCG levels.

A randomized clinical trial comparing 30 mg/m2 methotrexate given weekly to patients with low-risk GTN versus 1.25
mg/m2 of actinomycin D given every other week showed a higher complete response rate with actinomycin D.47

Patients with high-risk metastatic GTN are subdivided into 2 groups: those with a WHO score of less than 7 and
those with a score of 7 or higher and who are at high risk of therapy failure.

 Patients with a WHO score of less than 7 can be treated with single-agent chemotherapy (methotrexate or
actinomycin) because their chances of achieving a cure are high.48 AT least 1 additional course of
chemotherapy is administered after a normal serum hCG level is achieved.
 Patients with WHO scores of 7 or higher
o These patients are treated with a combination of etoposide, methotrexate, and actinomycin D
administered in the first week of a 2-week cycle and cyclophosphamide and vincristine (Oncovin)
administered in the second week.49,50,51,52 This is known as the EMA-CO regimen.
o Some substitute cisplatin and etoposide for cyclophosphamide and vincristine during the second
week. This is known as the EMA-CE regimen.53 Some reserve the EMA-CE regimen for patients in
whom EMA-CO fails.
o At least 2 additional courses of EMA-CO or EMA-CE are administered after a normal serum hCG
level.
o Patients with metastasis to the brain receive whole brain irradiation (3000 cGy) in combination with
chemotherapy.54,55,56 Corticosteroids (dexamethasone) with systemic effect are administered to
reduce brain edema. This is the most common approach in the United States.
o Early neurosurgical intervention for solitary lesions or stereotactic radiotherapy for multiple lesions
or solitary lesions in locations at high risk for surgical morbidity is used at the Charing Cross
Hospital in the United Kingdom and has been reported by physicians from Duke University in North
Carolina.57 At Charing Cross, neurosurgery is followed by moderate- and high-dose intravenous
 methotrexate and intrathecal methotrexate. However, intrathecal methotrexate is not routinely used
by others. A therapeutic level of methotrexate is achieved in the cerebrospinal fluid at doses of
methotrexate >600 mg/m2 given intravenously to patients with brain metastases.57
o In patients not receiving whole brain irradiation, the dose of methotrexate on day 1 of the EMA-CO
or EMA-CE regimen is increased to 1000 mg/m2. Instead of 4 doses of folinic acid, 8 doses are
given starting 24 hours after the methotrexate infusion. Patients with liver metastasis are
considered for liver irradiation (2000 cGy).58
 Patients with stage IV GTN are most often treated with multiagent chemotherapy, even when the WHO
score is less than 7, which is uncommon.
 After achieving 3-4 consecutive weekly normal serum hCG levels, patients with stage IV GTN are observed
with monthly serum hCG levels for 2 years. If the levels begin to rise during follow-up, the patient is
evaluated for possible intervening pregnancy, or persistent or recurrent disease.

Surgical Care

 A hysterectomy may be necessary in case of uncontrolled vaginal bleeding. Hysterectomy may reduce the
total number of chemotherapy cycles needed to achieve remission.36,37
 Uterine or hypogastric artery ligation or embolization of feeding vessels may be needed to control
hemorrhage. Hepatic artery embolization has been used successfully to control hemorrhage from hepatic
metastases.25
 A repeat D&C in the presence of persistent tissue on pelvic ultrasonography may reduce the number of
chemotherapy cycles needed to achieve remission.59
 Craniotomy may be needed to control bleeding and provide decompression.57,51
 Resection of solitary metastasis (eg, thoracotomy) or disease within the myometrium may help achieve a
remission.60,61,62

Consultations

A gynecologic oncologist experienced in managing GTN should be consulted.

Diet

No restrictions

Activity

No restrictions

Medication

The goals of pharmacotherapy are to reduce morbidity and to eradicate the neoplasm.

Antineoplastics

Gestational trophoblastic tumors are sensitive to many antineoplastic agents, especially those that act in the S phase
or the M phase of the cell cycle.

INTRODUCTION births.7 Common clinical presentations include

Gestational Trophoblastic Disease (GTD) is a vaginal
heterogeneous group of diseases that includes partial bleeding in early trimester, uterus larger than
and complete hydatidiform mole, invasive mole, gestational
choriocarcinoma and placental site trophoblastic age and absence of foetal parts after 20 weeks of
tumour. In recent years, new entities like epithelioid gestation. Ultrasonography is a reliable non-invasive
trophoblastic tumour have been added.1 The tool for diagnosis of GTD in the clinical setting.
incidence of GTD varies in different parts of the Since this group of disorders is now one of
world, for example, in Japan, the incidence is 2/1000 the highly curable neoplasms, early diagnosis and
deliveries while in Malaysia, the incidence of molar prompt treatment is necessary. The rates of GTD are
pregnancy and gestational trophoblastic neoplasia is decreasing and survival has dramatically improved in
2.8/1000 and 1.59/1000 deliveries respectively.2,3 different parts of the world.8,9
Meanwhile, in North America, its incidence is In Pakistan, few studies have been
reported up to 2.5/1000 pregnancies.4 Highest conducted in Lahore and Karachi to find out the
incidence of 12.1/1000 deliveries is reported from incidence of GTD, with an objective to compute the
Turkey.5 The malignant potential of this disease is epidemiological and clinical data in these areas.
higher in South East Asia where it is as high as 10– The objective of this study was to find out
15% in comparison to 2–4% in the western the frequency, common presentation, type of the
countries.6 GTD, extent of the disease, treatment modalities and
The exact incidence in Pakistan is not known the outcome in a cohort of local population.
but only one study has reported it to be 0.68/1000 PATIENTS AND METHODS
This retrospective, descriptive case review was
conducted at the Department of Gynaecology and hydatidiform mole, the serum β-HCG level was
Obstetrics, Nawabshah Medical College Hospital, undetectable within 3 months period.
from 1st Jan 2007 to 30th Dec 2007. The case Table-1: Socio-demographic data
records Parameters Number of Patients Percentage
of all these patients who were admitted with Age
trophoblastic disease and neoplasm were analysed <20 10 33.1
retrospectively regarding the age, parity, signs and 21–38 4 13.31
symptoms, duration of previous treatment, >38 16 53.3
histopathology, investigations, type of trophoblastic Parity
disease, type of surgical treatment, chemotherapy, 0–1 15 50
follow-up and mortality associated with this disease. 2–4 3 10
All those patients having trophoblastic disease with >4 12 40
J Ayub Med Coll Abbottabad 2009;21(1) Education
http://www.ayubmed.edu.pk/JAMC/PAST/21- Illiterate 19 63.3
1/Khairunnisa.pdf 95 Primary 8 26.6
elevated β-HCG, ultrasonic or histopathological Middle 2 6.6
evidence of the disease were included in the study. Graduation 1 3.33
Brain metastasis was detected through CT Scanning Socioeconomic condition
of the patients. Patients having irregular bleeding per Low 22 73.3
vagina without any evidence of trophoblastic disease Middle 7 23.3
were excluded. Socioeconomic status of patient was High 1 3.3
labelled as poor class if monthly income was up to Table-2: Clinical presentation
rupees 10,000 per months, middle class if income is Symptoms Number of Cases Percentage
up to 20,000 per months and upper class if monthly Bleeding P/V 11 36.6
income was more than 20000 rupees per months. Pain in lower abdomen 7 23.3
Data was analyzed using SPSS version 11.0. Passage of moles 5 16.6
RESULTS Hyperemesis gravidarum 4 13.3
There were total 1056 Obstetrical admissions during Dyspnoea 3 10
the study period which included 30 cases of GTD. Table-3: Type of gestational trophoblastic disease
Hence, the frequency of GTD was 28 per 1000 live Type of GTD Number of Cases Percentage
births in this study. H. Mole 21 70
Majority of the patients were of more than Invasive mole 7 23.3
of 38 year age 16 (53.3%) (Table-1). Out of these 30 Choriocarcinoma 2 6.6
patients, 15 (50%) were para one, while 12 (40%) DISCUSSION
were para more than four (Table-2). Gestational Trophoblastic Disease (GTD) is
The most common presenting symptom was characterised by the secretion of a distinct tumour
bleeding per vaginum 11 (36.3%) followed by pain in marker, the β-HCG. This condition is curable even in
lower abdomen 7 (23.3%), passage of moles 5 the presence of metastasis. The major
(16.6%), hyperemesis gravidarum 4 (13.3%) and wellestablished
dyspnoea in 3 (10.0%). risk factors for the disease are advanced
The antecedent pregnancy was hydatidiform maternal age and a past history of GTD.10
mole in 19 (63.3%) patients, abortion in 9 (30%) and Frequency of GTD in our study is 28 per 1000 live
full term pregnancy in 2 (66.6%) patients. births, which is quite significant. This frequency is
The gestational period in 18 (60%) patients, also higher within our country if compared to
in which disease was diagnosed was between 2–5 hospital based studies from Peshawar 11 and
months, in 9 (30%) patients, it was between 1–2 Karachi.12 The reason for the high frequency of the
months, and in only 3 (10%) patients, it was more GTD in this study might be the fact that the hospital
than 5 months. is a major referral centre with large catchment area.
Hydatidiform mole was diagnosed in 21 Another reason is that our patients had low
(70%) patients, invasive mole in 7 (23.3%) and socioeconomic and poor educational status (73.3% of
choriocarcinoma in 2 (6.6%) patients. No patient had patient had monthly income less than Rs. 10,000).
placental site trophoblastic tumour. A Korean study proved this fact by
Out of 30 patients, 29 underwent surgical decreasing the rate of incidence from 4.4 (1960s) to
treatment. In 25 (83.3%) patients, suction evacuation 1.6 (1990s) with improvement in medical care and to
was done and 4 (13.3%) cases underwent socioeconomic and educational changes.
hysterectomy. Indication of hysterectomy was J Ayub Med Coll Abbottabad 2009;21(1)
emergency presentation with heavy bleeding. http://www.ayubmed.edu.pk/JAMC/PAST/21-96
Seven (23.3%) patients received no adjuvant 1/Khairunnisa.pdf
chemotherapy. Twenty three (76.6%) patients Improvement in nutrition in another study
received did not support the suggestion of protein deficiency
chemotherapy. Among them 19 (82.6%) patients as an etiological factor.13
received single drug therapy (methotrexate alternate Another study conducted by Tham stated
with folinic acid) and 4 (17.3%) received multiple drug that the high incidence in Asia is generally attributed
therapy (EMA-CO regime). Before starting to low socioeconomic status and malnutrition.14
chemotherapy, opinion from oncologist in Atomic Maternal reproductive age is the most consistent risk
energy department was taken regarding type and factor for hydatidiform mole in every region and
dosage of chemotherapy. Chemotherapy was given ethnic group. In this study, disease was more
for common in the extreme of reproductive ages. It is
3–6 months. Among the 30 patients, 29 (96.7%) fully consistent with the findings of studies from
recovered and 1 (3.3%) died because of extensive Singapore6 and Karachi12.
disease (metastasising up to brain). Follow-up of the The available evidence suggests that
patients was carried out by clinical examination and hydatidiform mole arises as a consequence of
investigations such as serum β-HCG level, ultrasound defective ova.15 It is premature in young and post
examination and X-ray chest. Initially, it was carried mature in old ages. Antecedent pregnancy in invasive
out monthly, then after every 3 months till the β-HCG mole was hydatidiform mole while in
level was not detectable. In patients having benign choriocarcinoma both the patients had full-term
pregnancy one year back. Gynaecol 2003;17:925–42.
Vaginal bleeding was the most common 4. Lara FM, Alvarado AM, Candelaria M, Arce CS.
presenting symptom in this study and it is also Gestational
reported by other studies such as Kim16 and Zalel et trophoblastic disease. Experience at National Institute
al17. Another study conducted by Moodley et al, have of
also reported the same findings.2 Cancerology. Ginecol Obstet Mex 2005;73:308–14.
The diagnosis of trophoblastic disease was 5. Harma M, Harma M, Yurtseven S, Gungen N.
based on clinical and histopathological features, β- Gestational
HCG, trophoblastic disease in Sanliurfa, Southeast Anatolia,
ultrasonography, especially by using high resolution Turkey. Eur J Gynaecol Oncol 2005;26:306–8.
vaginal ultrasonography that could diagnose the 6. Trophoblastic disease. In: Shaw RW, Soutter WP,
disease much earlier. Ultrasonography and serum β- Stanton
HCG are the sensitive detectors of trophoblastic SL, (eds). Gynaecology. 3rd ed. Edinburgh: Churchill
disease. These tests are simple, non invasive, Livingstone; 2002.p.248–59.
inexpensive and yield quick result. Ultrasonography 7. Mumtaz F. Emergency hysterectomy after
and Doppler imaging are helpful in diagnosing gestational
gestational trophoblastic disease, in determining trophoblastic tumor: a case report. J Coll Physicians
whether invasive disease is present, in detecting Surg Pak
recurrent disease, and in following the effectiveness 1999;9:228–9.
of chemotherapy.18 Most of the patients in this study 8. Smith HO, Kohorn E, Cole LA. Choriocarcinoma
were having hydatidiform mole while 29.9% were and
having malignant trophoblastic disease in the form of gestational trophoblastic disease. Obstet Gynecol Clin
choriocarcinoma and invasive mole. North
Choriocarcinoma is a potentially fatal disease but Am 2005;32:661–84.
current management protocol has turned the 9. Cole LA, Kohorn E, Smith HO. Gestational
prognosis highly favourable. Izhar19 from Peshawar trophoblastic
has also reported cure rate of 80%. Like other diseases: management of cases with persistent low
studies, human
in this study, majority of patients with molar chorionic gonadotropin results. Obstet Gynecol Clin
pregnancy were treated with suction curettage, i.e. North
83.3% and only 4 patients needed hysterectomy; Am 2005;32:615–26.
seven had invasive mole and other had persistent 10. Loh KY, Sivalingam N, Suryani MY. Gestational
vaginal bleeding, which did not settle with trophoblastic disease. Med J Malaysia 2004;59:697–
evacuation and chemotherapy. Patients with 703.
malignant trophoblastic disease were treated with 11. Rauf B, Hassan L, Ahmed S. Management of
multiple agent chemotherapy and those who had gestational
increased serum β-HCG or those with persistent trophoblastic tumors: a five-year clinical experience. J
bleeding per vagina, after evacuation, were treated Coll
with single drug chemotherapy. The duration of Physicians Surg Pak 2004;14:540–4.
treatment ranged from 3–6 months with three doses 12. Talati NJ. The pattern of benign gestational
of chemotherapy till the serum β-HCG level was trophoblastic
undetectable. disease in Karachi. J Pak Med Assoc 1998;48:296–
Overall complete cure was achieved in 300.
96.7% patients in this study. However, 1 patient 13. Martin PM. High frequency of hydatidiform mole in
(3.3%) died during therapy. Main reasons of death in native
this patient was extensive disease (metastasising up Alaskans. Int J gynaecol Obstet 1978;15:395–6.
to brain) and poor general health. J Ayub Med Coll Abbottabad 2009;21(1)
CONCLUSION http://www.ayubmed.edu.pk/JAMC/PAST/21-
In this series, frequency of GTD was higher 1/Khairunnisa.pdf 97
compared to national and international literature. The 14. Tham BW, Everard JE, Tidy JA, Drew D, Hancock
disease was common in extremes of ages, low para BW.
and grand multiparous women. Hydatidiform mole Gestational trophoblastic disease in the Asian
was the commonest type of trophoblastic disease in population of
these patients. Most common presenting complaint Northern England and Wales. BJOG 2003;110:555–9.
was bleeding per vagina followed by pain in lower 15. Buckley JD. The epidemiology of molar pregnancy
abdomen. Patients with regular follow-up recovered and
fully while mortality was associated with choriocarcinoma. Clin Obstet Gynaecol 1984;27:153–
complications, delay in recovery and receiving no 9.
proper treatment. Proper management in the early 16. Kim SJ. Placental site trophoblastic tumor. Best
stages strongly influences the outcome of the Pract Res
diseases. Hence, emphasis should be given to detect Clin Obstet Gynaecol 2003;17:969–8.
the disease in its early stage to decrease the mortality 17. Zalel Y, Dgani R. Gestational trophoblastic
and morbidity from this condition. disease following
REFERENCES the evacuation of partial mole: a review of 66 cases.
1. Cheung AN. Pathology of gestational trophoblastic Eur J
disease. Obstet Gynecol Reprod Biol 1997;71:67–71.
Best Pract Res Clin Obstet Gynaecol 2003;17:849– 18. Jain KA. Gestational trophoblastic disease:
68. pictorial review.
2. Moodley M, Tunkyl K, Moodley J. Gestational Ultrasound Q 2005;21:245–53.
trophoblastic 19. Izhar R, Aziz-un-Nisa. Prognosis of gestational
syndrome: an audit of 112 patients. A South African choriocarcinoma at Khyber Teaching Hospital,
experience. Int J Gynecol Cancer 2003;13:234–9. Peshawar. J
3. Sivanesaratnam V. Management of gestational Ayub Med Coll Abbottabad 2003;15(2):45–8.
trophoblastic Address for Correspondence:
disease in developing countries. Best Pract Res Clin
Obstet
Dr. Gulfareen Haider, B/No: 530-A, Block C, Unit 8
Latifabad, Hyderabad, Pakistan. Cell: +92-300-
9379794
Email: [email protected]